Remus Pharmaceuticals (REMUS) Q2 FY27 Profit Growth Stalls Despite 53% Revenue Surge
Remus Pharmaceuticals posted a 53.5% jump in Q2 revenue, but profit barely moved as low-margin deals and subsidiary costs squeezed margins.
Remus Pharmaceuticals' Q2 FY27 revenue surged over 53% year-on-year, yet profit growth stalled at just 0.3% sequentially. The gap highlights a margin squeeze from low-margin transactional business and investments in new international subsidiaries.
For Remus Pharmaceuticals, the story this quarter is a tale of two businesses. Its core standalone operations in emerging markets are thriving with strong margins, but its consolidated results tell a different story of top-line growth that isn't reaching the bottom line.
Revenue soared to ₹614.1 crore, up 53.5% from a year ago and 35.4% from the previous quarter. Profit, however, grew just 14.2% year-on-year and was nearly flat sequentially at ₹24.7 crore. The net profit margin compressed to 4.0%, down 140 basis points from both last year and last quarter.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin
| Metric | CurrentQ2 FY27 (Sep 2026) | PreviousQ4 FY26 (Mar 2026) |
|---|---|---|
| Revenue (₹ Cr) | 614.12 | 453.43 |
| Profit (₹ Cr) | 24.66 | 24.58 |
| Net Profit Margin | 4.0% | 5.4% |
Why the Growth Didn't Translate to Profit
Management explained the disconnect on the earnings call. A significant portion of the revenue jump came from low-margin transactional business done to keep key customers happy. The AlphaStreet transcript notes these deals carried gross margins as low as 2%, inflating sales but adding little to profit.
Simultaneously, total expenses surged 56.3% year-on-year. This was driven by investments in branding, marketing, and free samples for the B2C push, alongside operational costs for new subsidiaries in markets like Guatemala and the Dominican Republic. These units are in a 'teething period,' as management called it, spending before they become profitable.
A Business Split in Two
The consolidated picture masks a stark divergence. According to the AlphaStreet call, the standalone business—the original high-margin export operation—saw revenue grow 32% with net profit soaring 57%. Its PAT margin expanded 470 basis points to a robust 30%.
The drag comes from the SP Global subsidiary and other new international arms. These entities, focused on US distribution and new market entry, operate at much thinner margins and are currently investing heavily. This mix shift is pulling the consolidated margin down.
The Path to Better Margins
Management is targeting a consolidated PAT margin of 5-7% in the long term. The key lever is the commercialization of newly approved, higher-margin products like semaglutide (a GLP-1 drug) and a growing portfolio of biosimilars and CNS therapies. The company told AlphaStreet it expects the second half of FY27 to be better than the first, with improved profitability.
Success hinges on converting over 1,400 pending product registrations into sales and scaling the B2C branded business. The recent approval for a ₹1 per share interim dividend signals confidence in cash generation, though consolidated operating cash flow was a modest ₹8 crore for the half.
Key Points
- Revenue growth of 53.5% YoY was fueled by international expansion but included low-margin transactional sales.
- Consolidated net profit margin fell to 4.0%, pressured by upfront costs for new subsidiaries and B2C branding.
- The high-margin standalone business grew profit 57%, but its contribution is diluted in consolidated numbers.
- Future margin improvement depends on launching newly approved specialty products like semaglutide.
Hexa Perspective
The quarter confirms Remus is successfully building scale and regulatory reach across 40+ countries. However, the current phase is capital-intensive, with profits growing far slower than sales. Investors are effectively funding market entry today for a payoff tomorrow.
The stock trades at a P/E of 21.6, a 43% discount to the industry average, reflecting this margin drag. The investment case rests on management's ability to shift the revenue mix toward higher-margin proprietary and branded products. Until that transition is visible in the consolidated margin, the stock may continue to discount the headline growth.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
